Woven EndoBridge Aneurysm Embolization (WEB) System
Microvention, Inc. · Decision date Mar 20, 2026
What did the FDA approve?
FDA records P170032/S019 as a supplement to PMA P170032, with the supplement type “Normal 180 Day Track No User Fee”. The recorded decision is approval, dated Mar 20, 2026.
FDA approval order statement
Approval of the revised protocol for the PAS1 PostMarket Surveillance-Long Term Safety post-approval study.
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- Neurology
- Decision date
- Mar 20, 2026
- FDA change category
- Postapproval Study Protocol
Regulatory record facts
- Identifier
- P170032/S019
- Regulatory pathway
- PMA supplement
- Applicant
- Microvention, Inc.
- Product code
- OPR
- Decision code
- APPR
- Decision date
- Mar 20, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Intrasaccular Flow Disruption Device.
- Applicant
- Microvention, Inc.
- Product code
- OPR
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P170032. Subsequent supplements may change the device or its indications.
FDA decision timeline
P170032 · Original PMA
Woven EndoBridge (WEB) Aneurysm Embolization System
P170032/S019 received
Application receipt date recorded by FDA.
P170032/S019 · FDA decision
Normal 180 Day Track No User Fee
P170032/S021 · Related supplement
Woven EndoBridge (WEB) Aneurysm Embolization System
P170032/S022 · Related supplement
Woven EndoBridge (WEB) Aneurysm Embolization System
P170032/S024 · Related supplement
Woven EndoBridge (WEB) Aneurysm Embolization System
Timeline entries are records held by MedtechLedger for P170032. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P170032
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Microvention, Inc. | PMA approval | Dec 31, 2018 | FDA | |
| Microvention, Inc. | PMA supplement | May 1, 2026 | FDA | |
| Microvention, Inc. | PMA supplement | May 28, 2026 | FDA | |
| Microvention, Inc. | PMA supplement | Oct 27, 2026 | FDA |
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Microvention, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 35 Enterprise, Aliso Viejo, CA, 92656
Sources and methodology
- Original FDA record: P170032/S019
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 21, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


